Sentences with phrase «with vaccine efficacy»

We're trying to better understand the barriers to flu vaccination, along with vaccine efficacy issues.

Not exact matches

Most biotechs would have shuttered a clinical program that showed absolutely no efficacy whatsoever in a late - stage trial, but Novavax has instead doubled down on RSV by going forth with its phase 3 trial of the RSV F vaccine for infants via maternal immunization, and begun planning for another trial in older adults that's reportedly on track to kick off in 2018.

Given questions about how long the vaccine is effective for, she questioned the efficacy of giving shots to girls as young as 11 years old in parts of the world (such as the U.S.) where women regularly undergo safety Pap screening repeatedly over their lifetimes, saying that the chances of their contracting cervical cancer may be less than the «small» risks associated with the vaccine.

Together with researchers at the CNRS, the group has demonstrated the efficacy of RNA - based vaccines produced using the new method against plant virus infections.

«Obviously one would want to have a higher efficacy when it comes to severe disease, but we're still hoping we can improve on the vaccine as we go along with the trials.»

He and Bonomo compared the efficacy of the egg - based vaccine with an experimental vaccine produced from insect cells via reverse genetics.

In collaboration with many researchers (graduate students, postdocs, and faculty elsewhere), we have examined the role of cross-immunity on the evolution and dynamics of influenza; the impact of behavioral changes, long periods of infectiousness, variable infectivity, co-infections, prostitution, social networks, and vaccine efficacy on HIV dynamics; the role of exogenous re-infection, variable progression rates, vaccination, public transportation, close and casual contacts on tuberculosis dynamics and control; the impact of life - history vector dynamics on dengue epidemics; and on the identification of time - response scales for epidemics of foot and mouth disease.

For the moment, the CYD - TDV vaccine is the best we have; however, with 56 % efficacy it will never be a single solution.

Qin says subsequent experiments for testing vaccine or antiviral drug efficacy should use contemporary strains with the S139N mutation.

«A successful vaccine requires a fine balance between efficacy and safety — vaccines made from attenuated live viruses generally offer fast and durable immunity, but sometimes with the trade - off of reduced safety, whereas inactivated and subunit viruses often provide enhanced safety but may require several doses initially and periodic boosters.

One of the vaccines, which is based on a recombinant vesicular stomatitis virus expressing the glycoprotein of the Zaire strain of the Ebola virus (VSV - ZEBOV), was recently shown to be extremely effective with 100 per cent efficacy against the lethal Ebola virus disease in WHO - funded studies carried out in Guinea and Sierra Leone.

«Nevertheless,» they state, «the model provides a useful perspective on how vaccine properties and strategic choices affect the relative size and severity of projected epidemics,» and conclude that, «a vaccine like the Sanofi - Pasteur candidate can be an effective tool for reducing the dengue burden, although a vaccine with waning efficacy would require a booster program.»

At the meeting, GlaxoSmithKline (GSK) of Rixensart, Belgium, which has the vaccine furthest in development, spelled out how it might scale up production in parallel with the safety and efficacy trials now under way so that the product could be ready for wider distribution by April if warranted.

Still, says Weiner, there are ways to enhance efficacy, for instance by trying more or different genes or by using a so - called prime - boost strategy, in which the DNA vaccine is followed by a shot with the protein subunits themselves.

For influenza we offer the ferret model, the «gold standard» for infections with human influenza viruses, which will be used to assess the efficacy of vaccine candidates.

The correlate study conducted by the US Military along with Duke University has found clues that will enable scientists to improve the current vaccine's efficacy level.

The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.

A new paper published in the Journal of Allergy and Clinical Immunology has reported on a multicentre trial to test the safety and clinical efficacy of a new vaccine against grass pollen allergy in patients with grass pollen — induced rhinitis and controlled asthma.

The full paper that this statement is in response to can be found at: Niederberger et al. 2018 Safety and efficacy of immunotherapy with the recombinant B - cell epitope — based grass pollen vaccine BM32.

They could potentially play a role in the event of a pandemic, in this case by «antigen sparing», allowing efficacy with lower doses of the influenza antigen — thereby allowing faster production of more doses of the vaccine as early as possible in the pandemic.

The efficacy of the best vaccines was very high in mice, providing complete protection with a single dose.

The development track will begin with a Phase I trial to test the vaccine regimen's safety and immunogenicity and depending on those study results, a larger efficacy study will follow.

The vaccines were evaluated for immunogenicity and efficacy; however, because of the previous report of immunopathology on challenge of ferrets and nonhuman primates that had been vaccinated with a whole virus adjuvanted vaccine and mice that had been vaccinated with a VLP vaccine, the primary orientation was to assess for immunopathology among animals in relation to type of vaccine, dosage, serum antibody responses, and virus infection.

She is involved with vaccine design and efficacy screening in different models of mycobacterial infections.

The other two pandemic influenza projects focus on the efficacy of recombinant protein and VLP pandemic influenza vaccines combined with IDRI's adjuvant technology.

I am told by the medical scientists that a medical vaccine with 80 percent efficacy is considered a very good vaccine.

«This finding is consistent with a hypothesis generated out of the follow - up studies to the RV144 HIV vaccine trial in Thailand that showed the first efficacy in humans,» noted COL Nelson Michael, Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

Superior efficacy of a human immunodeficiency virus vaccine combined with antiretroviral prevention in simian - human immunodeficiency virus - challenged nonhuman primates.

Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.

She began to question the safety and efficacy of vaccines after observing many patients with kidney failure after receiving vaccinations.

Introducing VANGUARD ® CIV H3N2 / H3N8, a bivalent canine flu vaccine with demonstrated safety and efficacy for protection against both highly contagious H3N2 and H3N8 strains of canine influenza virus (CIV).

Bacterial vaccines have low efficacy rates coupled with high incidence of adverse reactions.

Notably, immunogenicity and protection efficacy conferred by the NS1 mutant H3N8 CIVs was better than that observed with a CIV H3N8 inactivated influenza vaccine (IIV).

«It showcases our confidence in the safety and efficacy of our equine FLUVAC INNOVATOR ® line of vaccines with the MetaStim ® adjuvant.

Coupled with the often heated and sometimes emotional national discussions regarding the safety and efficacy of vaccines, you may wonder if it's worth vaccinating your pet at all.

Work has been completed on the formulation of the new vaccine, with clinical trials and efficacy studies yet to be completed.

There have been suggestions that CPV - 2c presents challenges in terms of virulence, diagnostic testing, or vaccine efficacy — but so far, studies have shown that current vaccine products as well as diagnostic tests function similarly with CPV - 2c as with the other variants.

With regard to the controversial leptospirosis vaccine and its known ability to stimulate anaphylaxis and encephalitis, its poor record of efficacy, and the fact that leptospirosis is a relatively rare disease, I go along with Dr Schultz's own views that this vaccine comes with more risks than benefits, and that its use is questionaWith regard to the controversial leptospirosis vaccine and its known ability to stimulate anaphylaxis and encephalitis, its poor record of efficacy, and the fact that leptospirosis is a relatively rare disease, I go along with Dr Schultz's own views that this vaccine comes with more risks than benefits, and that its use is questionawith Dr Schultz's own views that this vaccine comes with more risks than benefits, and that its use is questionawith more risks than benefits, and that its use is questionable.

We don't know the efficacy of Red Rocks Biologicals Crotalus Atrox Toxoid (rattlesnake vaccine) because no one has, or ever is, going to do controlled studies, where they inject dogs with snake venom and compare vaccinated dogs to unvaccinated dogs, for obvious humane reasons.

Efficacy of three vaccines in protecting Western Scrub - Jays (Aphelocoma californica) from experimental infection with West Nile virus: implications for vaccination of Island Scrub - Jays (Aphelocoma insularis).